Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + radiotherapy + autologous tumor-infiltrating lymphocytes
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University Cancer Center
- Modality
- Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
This investigational combination therapy, developed by Sun Yat-sen University Cancer Center, integrates autologous tumor-infiltrating lymphocytes (TILs) with standard-of-care cisplatin-based concurrent chemoradiotherapy (CCRT) for patients with locally advanced cervical carcinoma (FIGO stage IIIA-IVA). The treatment protocol involves isolating T cells from the patient's own tumor tissue, expanding them ex vivo using interleukin-2 and anti-CD3 antibodies under Good Manufacturing Practice (GMP) conditions, and re-infusing them following the completion of chemoradiotherapy. This approach aims to leverage the debulking and sensitizing effects of CCRT alongside the targeted, long-term anti-tumor immunity provided by TILs to improve outcomes and prevent recurrence in high-risk cervical cancer patients.
- Other names
- Concurrent chemoradiation therapy + tumor-infiltrating lymphocytes-Sun Yat-sen University-cervical carcinomaTILs with Concurrent ChemoradiotherapyStudy of Tumor Infiltrating Lymphocytes Following Concurrent Chemoradiotherapy
Beyond the preview
Go deeper on cisplatin + radiotherapy + autologous tumor-infiltrating lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + radiotherapy + autologous tumor-infiltrating lymphocytes.